New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 12, 2012
07:42 EDTAHS, CPHD, CLDX, IART, BIOS, USPH, PBTH, ARNA, DXCM, INSMOppenheimer to host a conference
23rd Annual Healthcare Conference is being held in New York on December 12-13 with webcasted presentations to begin on December 12 at 7:45 am; not all company presentations may be webcasted. Webcast Link
News For AHS;DXCM;ARNA;PBTH;USPH;BIOS;IART;CLDX;CPHD;INSM From The Last 14 Days
Check below for free stories on AHS;DXCM;ARNA;PBTH;USPH;BIOS;IART;CLDX;CPHD;INSM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 1, 2014
09:27 EDTARNAOn The Fly: Pre-market Movers
Subscribe for More Information
05:48 EDTARNAArena Pharmaceuticals reports Q2 EPS 3c, consensus (11c)
Subscribe for More Information
July 31, 2014
16:46 EDTAHSAMN Healthcare sees Q3 revenue $254M-258M, consensus $253.59M
Subscribe for More Information
16:45 EDTAHSAMN Healthcare reports Q2 adjusted EPS 19c, consensus 16c
Subscribe for More Information
16:35 EDTINSMPoint72 reports 5.4% passive stake in Insmed
Subscribe for More Information
08:50 EDTCLDXCelldex management to meet with Leerink
Meeting to be held on Boston on August 5 hosted by Leerink.
July 30, 2014
16:50 EDTCPHDCepheid updates status of group purchasing organization agreement
Cepheid announced that its group purchasing organization, or GPO, contract with Premier will end on September 30. Customers currently purchasing through the Premier GPO will be able to continue their relationship with Cepheid through other GPOs including Amerinet, Baycare, HPA, MedAssets, Novation, and ROi, in addition to the recently announced agreement with HealthTrust, or directly with Cepheid.
08:04 EDTARNAArena Pharmaceuticals and Eisai announce results of Lorcaserin Phase 2 trial
Arena Pharmaceuticals and Eisai announced that an article based on post-hoc analyses from the three pivotal Phase 3 trials of lorcaserin was recently published in the official peer reviewed journal of The Obesity Society. The objective of these analyses was to identify whether there is an early treatment milestone that can predict greater than or equal to 5% weight loss at one year in patients treated with lorcaserin. Belviq is a serotonin 2C receptor agonist approved in the U.S. as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in obese or overweight adults with at least one weight-related medical condition, such as high blood pressure, high cholesterol, or type 2 diabetes.
July 29, 2014
08:19 EDTARNAArena Pharma' and Eisai announce nomination of BELVIQ by Gallen Foundation
Eisai and Arena Pharmaceuticals (ARNA) announced that BELVIQ, or lorcaserin HCl, has been nominated by the Galien Foundation and Awards Committee for the 2014 Prix Galien USA Award in the Best Pharmaceutical Agent category. BELVIQ was previously nominated for this award in 2013.
July 22, 2014
12:01 EDTAHSAMN Healthcare promotes Jeanette Sanchez to Chief Informatoin Officer
Subscribe for More Information
July 21, 2014
08:11 EDTARNAArena Pharma' subsidiary enters into agreement for Belviq with Teva subsidiary
Subscribe for More Information
July 18, 2014
09:44 EDTCPHDCepheid trades sharply lower after earnings, levels to watch
Subscribe for More Information
09:24 EDTCPHDOn The Fly: Pre-market Movers
Subscribe for More Information
08:31 EDTBIOSBioScrip appoints Thomas Pettit as Senior VP and COO effective immediately
Pettit will succeed Richard Jenkins, a Managing Director at Alvarez & Marsal, who had served as BioScrip's Interim COO since November 2013. To ensure a smooth transition, Jenkins will continue as a consultant to the company for a short period of time.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use